Viking Therapeutics
VKTX
179 hedge funds and large institutions have $854M invested in Viking Therapeutics in 2023 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 63 increasing their positions, 49 reducing their positions, and 43 closing their positions.
169% more call options, than puts
Call options by funds: $41.1M | Put options by funds: $15.3M
29% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 49
2.22% more ownership
Funds ownership: 74.91% → 77.13% (+2.2%)
7% less funds holding
Funds holding: 193 → 179 (-14)
28% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 43
30% less capital invested
Capital invested by funds: $1.21B → $854M (-$358M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$22.8M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$21.5M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
+$14.7M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$11.8M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$8.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$11.2M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$10.7M |
| 3 |
RI
RTW Investments
New York
|
-$10.6M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$9.7M |
| 5 |
PA
Perceptive Advisors
New York
|
-$6.31M |
VKTX Hedge Fund Activity: Q3 2023 in Review
179 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q3 2023, worth a combined $854M — down 30% from $1.21B a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of VKTX and 31 opened new positions — a net loss of 12 holders — while 49 trimmed existing stakes and 63 added.
The largest buyer was State Street, adding an estimated $22.8M. The largest seller was Victory Capital Management, cutting an estimated $11.2M.
- 179 institutional investors held Viking Therapeutics (VKTX) as of Q3 2023, down from 193 in Q2 2023.
- Funds reported $854M of Viking Therapeutics stock for Q3 2023, down 30% quarter-over-quarter.
- 31 funds opened new Viking Therapeutics positions in Q3 2023 and 43 closed out, a net change of -12 holders.
- The largest Viking Therapeutics buyer in Q3 2023 was State Street, an estimated $22.8M added.
- The largest Viking Therapeutics seller in Q3 2023 was Victory Capital Management, an estimated $11.2M sold.
Based on aggregated 13F filings for Q3 2023.